<DOC>
	<DOCNO>NCT00523406</DOCNO>
	<brief_summary>To assess CNV treatment effect PDT verteporfin combination IVTA use reduce fluence compare standard fluence .</brief_summary>
	<brief_title>Comparison Reduced Fluence Versus Standard Photodynamic Therapy ( Combination With Intravitreal Triamcinolone Acetate )</brief_title>
	<detailed_description>Age-related macular degeneration ( AMD ) far common disorder group irreversible cause visual disability . AMD lead dysfunction loss photoreceptors central retina . Neovascular AMD affect visual function early disease process severely compromise highly developed function macula , perception detail , central fixation , color vision , read ability . AMD-related visual impairment associate loss autonomy quality life . Currently , laser photocoagulation , photodynamic therapy ( PDT ) verteporfin usually combine intravitreal triamcinolone acetonide ( IVTA ) prove treatment subfoveal choroidal neovascularisation ( CNV ) . Laser photocoagulation limit select case . Photodynamic therapy use verteporfin provide promising data regard improvement visual acuity absence fluorescein leakage . PDT recently successfully combine intravitreal injection corticosteroid triamcinolone acetonide . Yet , PDT also lead damage surround normal choroidal vessel . A pilot trial compare low fluence ( 300 mW/cm² ) standard fluence ( 600 mW/cm² ) demonstrate trend improve outcomes use low fluence regimen ( VIM study ) . However , vascular mechanism choroidal damage examine , study group small evaluate vision outcome parameter . Combined IVTA , low fluence effect PDT may sufficient CNV occlusion physiological choroid spar collateral damage . The aim study compare reduce fluence standard fluence PDT use verteporfin IVTA CNV secondary AMD .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Inclusion criterion : Patients 50 year age great . Patients subfoveal choroidal neovascularization lesion secondary AMD . CNV lesion study eye ≤ 4 disc area great linear dimension . Patients BCVA score good 20/400 study eye use ETDRS . Only one eye assess study . If eye eligible , one bad visual acuity select treatment study unless , base medical reason , investigator deems eye appropriate candidate treatment study . Prior treatment study eye verteporfin , externalbeam radiation therapy , subfoveal focal laser photocoagulation , vitrectomy , submacular surgery , transpupillary thermotherapy . Previous current intravitreal drug delivery ( e.g. , intravitreal corticosteroid injection device implantation ) study eye . Laser photocoagulation ( juxtafoveal extrafoveal ) study eye within one month precede Visit 1 . History glaucoma filtration surgery , corneal transplant surgery extracapsular extraction cataract phacoemulsification within six month precede Visit 1 , history postoperative complication within last 12 month precede Visit 1 study eye ( uveitis , cyclitis etc. ) . History uncontrolled glaucoma study eye ( defined intraocular pressure ≥ 25 mmHg despite treatment antiglaucoma mediation ) . Aphakia absence posterior capsule study eye . Presence retinal pigment epithelial tear involve macula study eye . Any concurrent intraocular condition study eye ( e.g. , cataract diabetic retinopathy ) , opinion investigator , could either require medical surgical intervention threemonth study period prevent treat visual loss might result condition . Active intraocular inflammation ( grade trace ) study eye . Any active infection involve eyeball adnexa . Vitreous hemorrhage history rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye . Ocular condition require chronic concomitant therapy systemic topical ocular corticosteroid . Chronic concomitant therapy define multiple dos take daily three consecutive day time within six month prior screen course study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>choroidal neovascularisation ,</keyword>
	<keyword>vision ,</keyword>
	<keyword>macula ,</keyword>
	<keyword>macular degeneration</keyword>
	<keyword>optical coherence tomography</keyword>
	<keyword>neovascular age relate macular degeneration</keyword>
</DOC>